Copper-67 SAR-bisPSMA updates

Barchart · 10/16 08:03

SYDNEY, Oct. 16, 2024 /PRNewswire/ -- 

HIGHLIGHTS

Cohort 4 - SECuRE Trial

Expanded Access Program (EAP) update: Multi-dose 67Cu-SAR-bisPSMA

Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to share a number of updates on the 67Cu-SAR-bisPSMA program.

Read more at prnewswire.com